London-based deep tech company StandardX has raised £10 million in seed funding to tackle a growing supply problem affecting medicine, energy and other advanced industries.

The round was led by Vsquared Ventures and East X Ventures, with additional backing from firstminute capital, the UK Innovation and Science Seed Fund managed by Future Planet Capital, Brevan Howard Macro Venture and Geometry.

Building a new isotope supply chain

StandardX is developing an accelerator-based refinery designed to manufacture rare isotopes at commercial scale.

Isotopes are critical to areas including cancer diagnosis, radiopharmaceuticals, medical research and energy. Yet production today remains concentrated across a relatively small number of ageing and capacity-constrained facilities.

That creates a difficult problem for healthcare companies and researchers. Demand for advanced medical treatments is increasing, while the materials needed to develop and deliver some of those treatments remain difficult to source. StandardX believes a more flexible production model could help address that gap.

The company's system is designed to produce a broader range of isotopes from a standard industrial footprint, allowing facilities to potentially be located closer to the organisations that need them.

From cancer treatment to fusion energy

StandardX plans to begin with isotopes used in cancer diagnosis and treatment. The company expects to supply its first isotopes to a medical research partner in 2027, with industrial-scale production targeted from 2029.

The technology could eventually have another major application.

StandardX is also working towards producing tritium, a scarce isotope used as fuel in fusion energy research. The company says it has already signed agreements with fusion developers to support future tritium production.

That gives the business two potential markets, with healthcare providing an immediate application while fusion could create a much larger industrial opportunity as the technology develops.

Turning deep tech into infrastructure

Founded in 2025 by nuclear engineers Richard Pearson, CEO, and Ross Allen, CTO, StandardX has already built a team of 15 scientists, engineers and operators with backgrounds including SpaceX, Oxford University, Cambridge University, Fermilab and the UK Atomic Energy Authority.

The new funding will help the company expand its team, secure its first industrial site in London and begin building its first accelerator-based refinery.

For investors, the raise reflects a broader interest in deep tech businesses solving physical supply constraints rather than purely software-based problems. For StandardX, the immediate challenge is turning its technology into working infrastructure that can deliver reliable isotope production.

If successful, the company could sit at the intersection of healthcare, advanced manufacturing and fusion energy, three sectors where access to critical materials could become increasingly important.

Could scalable isotope production become a major piece of the future of cancer treatment and fusion energy?

💬 Join Our Discord Community

Don't build your business alone. Join thousands of founders, entrepreneurs, and startup professionals sharing funding opportunities, industry news, events, partnerships, and practical advice every day.

Join Our Discord Community